Latest Pharma and Biotech News
Pharmaceutical
2 July 2025 A federal judge has blocked the US Department of Health and Human Services from moving forward with a major workforce reduction and agency overhaul, finding that the changes may violate federal law and cause lasting disruption.
Today's issue
Refine Search
Pharmaceutical
A new European Commission strategy promises to lift life sciences in the region out of a two-decade slump by tackling regulatory barriers, boosting clinical trials and supporting biotech innovation. The plan was unveiled in Brussels on July 2 and is being described by industry as a long-overdue course correction. 3 July 2025
Pharmaceutical
The UK government today launched its 10 Year Health Plan for the National Health Service (NHS), promising a "new era." A new network of neighborhood health hubs will be set up to shift care out of hospitals and into the community. 3 July 2025
Biotechnology
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended Fruzaqla (fruquintinib) be reimbursed by the National Health Service (NHS), Japanese drug major Takeda’s local subsidiary revealed today. 3 July 2025
Biotechnology
Swiss pharma giant Novartis has announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx (secukinumab) in adults with newly-diagnosed or relapsing giant cell arteritis (GCA). 3 July 2025
Biotechnology
The US Food and Drug Administration has granted accelerated approval to sunvozertinib (trade name Zegfrovy) from Dizal (Jiangsu) Pharmaceutical for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). 3 July 2025
Pharmaceutical
US-Japan venture capital firm AN Venture Partners has wrapped up its first fund at $200 million, marking one of the largest biotech funds focused on Japan to date. The new vehicle, called AN Venture Partners I, is backed by over 20 limited partners, including Japanese drugmakers Shionogi and Otsuka Pharmaceutical. 3 July 2025
Biotechnology
The US Food and Drug Administration (FDA) has provided an update on the risk of myocarditis after receiving an mRNA COVID-19 vaccine, noting the risk is higher in young men. 3 July 2025
Biotechnology
French biotech MaaT Pharma has signed a licensing and distribution agreement with UK-based Clinigen, positioning the company for a potential commercial rollout of its lead microbiome therapy in Europe. 3 July 2025
Biotechnology
US biopharma Apellis Pharmaceuticals announced a capped royalty purchase agreement with Swedish Orphan Biovitrum where Apellis will receive up to $300 million in exchange for 90% of Apellis’ future ex-US royalties for Aspaveli (systemic pegcetacoplan). 3 July 2025
Biotechnology
The US Food and Drug Administration (FDA) has granted accelerated approval for Regeneron Pharmaceuticals’ Lynozyfic (linvoseltamab-gcpt) to treat adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti CD38 monoclonal antibody. 3 July 2025
Pharmaceutical
The chronic kidney disease (CKD) anemia market across the seven major markets (7MM) is forecast to grow at a compound annual growth rate (CAGR) of 1.7% from $4.4 billion in 2024 to $5.3 billion in 2034. 3 July 2025
Biotechnology
US biopharma Syntis Bio, which is developing oral therapies for obesity, diabetes and rare diseases, has announced the close of a $33 million oversubscribed Series A financing. 2 July 2025
Biotechnology
Swiss biopharma company BioVersys (today announced a research and exclusive license option agreement with the Japanese pharmaceutical company, Shionogi to jointly develop novel ansamycin leads from BioVersys’ BV500 program into clinical candidates. 2 July 2025
Pharmaceutical
Australian neurodegenerative diseases specialist Neurizon Therapeutics has agreed an exclusive global license agreement with Elanco Animal Health and affiliates for monepantel, the active pharmaceutical ingredient in NUZ-001. 2 July 2025
Pharmaceutical
A federal judge has blocked the US Department of Health and Human Services from moving forward with a major workforce reduction and agency overhaul, finding that the changes may violate federal law and cause lasting disruption. 2 July 2025
Biotechnology
US pharma giant Merck & Co today revealed that the US Food and Drug Administration (FDA) has accepted and granted priority review for a supplemental Biologics License Application (sBLA) to update the US product label for Winrevair (sotatercept-csrk) based on the Phase III ZENITH trial. 2 July 2025
Pharmaceutical
Alnylam Pharmaceuticals has won European Commission approval for Amvuttra (vutrisiran) to treat transthyretin amyloidosis with cardiomyopathy (ATTR-CM), positioning the drug as a likely challenger to entrenched therapies in a market expected to see rapid evolution. 2 July 2025
Biotechnology
Taiwanese biotech HanchorBio has signed a licensing agreement with China’s Shanghai Henlius Biotech. 2 July 2025
All news
Pharmaceutical
A new European Commission strategy promises to lift life sciences in the region out of a two-decade slump by tackling regulatory barriers, boosting clinical trials and supporting biotech innovation. The plan was unveiled in Brussels on July 2 and is being described by industry as a long-overdue course correction. 3 July 2025
Pharmaceutical
The UK government today launched its 10 Year Health Plan for the National Health Service (NHS), promising a "new era." A new network of neighborhood health hubs will be set up to shift care out of hospitals and into the community. 3 July 2025
Biotechnology
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended Fruzaqla (fruquintinib) be reimbursed by the National Health Service (NHS), Japanese drug major Takeda’s local subsidiary revealed today. 3 July 2025
Biotechnology
Swiss pharma giant Novartis has announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx (secukinumab) in adults with newly-diagnosed or relapsing giant cell arteritis (GCA). 3 July 2025
Biotechnology
The US Food and Drug Administration has granted accelerated approval to sunvozertinib (trade name Zegfrovy) from Dizal (Jiangsu) Pharmaceutical for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). 3 July 2025
Pharmaceutical
US-Japan venture capital firm AN Venture Partners has wrapped up its first fund at $200 million, marking one of the largest biotech funds focused on Japan to date. The new vehicle, called AN Venture Partners I, is backed by over 20 limited partners, including Japanese drugmakers Shionogi and Otsuka Pharmaceutical. 3 July 2025
Biotechnology
The US Food and Drug Administration (FDA) has provided an update on the risk of myocarditis after receiving an mRNA COVID-19 vaccine, noting the risk is higher in young men. 3 July 2025
Biotechnology
French biotech MaaT Pharma has signed a licensing and distribution agreement with UK-based Clinigen, positioning the company for a potential commercial rollout of its lead microbiome therapy in Europe. 3 July 2025
Biotechnology
US biopharma Apellis Pharmaceuticals announced a capped royalty purchase agreement with Swedish Orphan Biovitrum where Apellis will receive up to $300 million in exchange for 90% of Apellis’ future ex-US royalties for Aspaveli (systemic pegcetacoplan). 3 July 2025
Biotechnology
The US Food and Drug Administration (FDA) has granted accelerated approval for Regeneron Pharmaceuticals’ Lynozyfic (linvoseltamab-gcpt) to treat adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti CD38 monoclonal antibody. 3 July 2025
Pharmaceutical
The chronic kidney disease (CKD) anemia market across the seven major markets (7MM) is forecast to grow at a compound annual growth rate (CAGR) of 1.7% from $4.4 billion in 2024 to $5.3 billion in 2034. 3 July 2025
Biotechnology
US biopharma Syntis Bio, which is developing oral therapies for obesity, diabetes and rare diseases, has announced the close of a $33 million oversubscribed Series A financing. 2 July 2025
Biotechnology
Swiss biopharma company BioVersys (today announced a research and exclusive license option agreement with the Japanese pharmaceutical company, Shionogi to jointly develop novel ansamycin leads from BioVersys’ BV500 program into clinical candidates. 2 July 2025
Pharmaceutical
Australian neurodegenerative diseases specialist Neurizon Therapeutics has agreed an exclusive global license agreement with Elanco Animal Health and affiliates for monepantel, the active pharmaceutical ingredient in NUZ-001. 2 July 2025
Pharmaceutical
A federal judge has blocked the US Department of Health and Human Services from moving forward with a major workforce reduction and agency overhaul, finding that the changes may violate federal law and cause lasting disruption. 2 July 2025
Biotechnology
US pharma giant Merck & Co today revealed that the US Food and Drug Administration (FDA) has accepted and granted priority review for a supplemental Biologics License Application (sBLA) to update the US product label for Winrevair (sotatercept-csrk) based on the Phase III ZENITH trial. 2 July 2025
Pharmaceutical
Alnylam Pharmaceuticals has won European Commission approval for Amvuttra (vutrisiran) to treat transthyretin amyloidosis with cardiomyopathy (ATTR-CM), positioning the drug as a likely challenger to entrenched therapies in a market expected to see rapid evolution. 2 July 2025
Biotechnology
Taiwanese biotech HanchorBio has signed a licensing agreement with China’s Shanghai Henlius Biotech. 2 July 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze